NRIX Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 72% planned / 28% discretionary
Largest single sale: $580.5K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| van Houte Hans 2 fills | Chief Financial Officer | Sell 10b5-1 | 4,769 | $15.63 | $74.6K | 44,214 −9.7% of holding | |
| Ring Christine | Chief Legal Officer | Sell 10b5-1 | 6,113 | $25.83 | $157.9K | 4,406 −58.1% of holding | |
| Ring Christine 2 fills | Chief Legal Officer | Sell 10b5-1 | 10,602 | $25.84 | $274.0K | 11,594 −47.8% of holding | |
| Hansen Gwenn | Chief Scientific Officer | Sell 10b5-1 | 1,452 | $26.80 | $38.9K | 123,452 −1.2% of holding | |
| Hansen Gwenn | Chief Scientific Officer | Sell | 3,957 | $26.28 | $104.0K | 123,452 −3.1% of holding | |
| Ring Christine | Chief Legal Officer | Sell | 3,957 | $26.28 | $104.0K | 15,335 −20.5% of holding | |
| van Houte Hans | Chief Financial Officer | Sell | 2,834 | $26.28 | $74.5K | 47,514 −5.6% of holding | |
| Hansen Gwenn | Chief Scientific Officer | Sell 10b5-1 | 1,452 | $25.00 | $36.3K | 117,227 −1.2% of holding | |
| GREGORY JULIA P | Director | Sell | 22,583 | $23.40 | $528.5K | 10,750 −67.7% of holding | |
| Ring Christine | Chief Legal Officer | Sell 10b5-1 | 5,786 | $23.19 | $134.1K | 9,110 −38.8% of holding | |
| Ring Christine 2 fills | Chief Legal Officer | Sell 10b5-1 | 5,787 | $25.76 | $149.1K | 9,510 −37.8% of holding | |
| Hansen Gwenn | Chief Scientific Officer | Sell 10b5-1 | 1,452 | $25.47 | $37.0K | 117,227 −1.2% of holding | |
| Hansen Gwenn | Chief Scientific Officer | Sell 10b5-1 | 4,356 | $25.00 | $108.9K | 117,227 −3.6% of holding | |
| van Houte Hans 2 fills | Chief Financial Officer | Sell 10b5-1 | 4,761 | $24.36 | $116.0K | 43,133 −9.9% of holding | |
| Hansen Gwenn 2 fills | Chief Scientific Officer | Sell 10b5-1 | 4,111 | $24.36 | $100.1K | 119,838 −3.3% of holding | |
| Ring Christine | Chief Legal Officer | Sell 10b5-1 | 16,589 | $23.05 | $382.4K | 9,110 −64.6% of holding | |
| Hansen Gwenn | Chief Scientific Officer | Sell | 3,847 | $23.38 | $90.0K | 121,338 −3.1% of holding | |
| Ring Christine | Chief Legal Officer | Sell | 3,847 | $23.38 | $90.0K | 19,912 −16.2% of holding | |
| van Houte Hans | Chief Financial Officer | Sell | 2,845 | $23.38 | $66.5K | 44,927 −6% of holding | |
| Ring Christine | Chief Legal Officer | Sell 10b5-1 | 11,008 | $23.56 | $259.4K | 13,579 −44.8% of holding | |
| Ring Christine | Chief Legal Officer | Sell 10b5-1 | 28,935 | $20.06 | $580.5K | 13,579 −68.1% of holding | |
| Hansen Gwenn | Chief Scientific Officer | Sell 10b5-1 | 5,394 | $20.00 | $107.9K | 115,005 −4.5% of holding | |
| Ring Christine | Chief Legal Officer | Sell 10b5-1 | 8,148 | $16.60 | $135.3K | 13,579 −37.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.